首页> 外文OA文献 >Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

【2h】

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

机译：正在进行的MGA271（Fc优化的人源化抗B7-H3单克隆抗体）I期剂量递增研究的中期结果，用于难治性B7-H3表达肿瘤或脉管系统表达B7-H3的肿瘤患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
John Powderly; Gregory Cote; Keith Flaherty; Russell Z Szmulewitz; Antoni Ribas; Jeffrey Weber; Deryk Loo; Jan Baughman; Francine Chen; Paul Moore; Ezio Bonvini; James Vasselli; Jon Wigginton; Roger Cohen; Howard Burris; Bartosz Chmielowski;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 [J] . John Powderly, Gregory Cote, Keith Flaherty, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：正在进行的MGA271（Fc优化的人源化抗B7-H3单克隆抗体）I期剂量递增研究的中期结果，用于难治性B7-H3表达肿瘤或脉管系统表达B7-H3的肿瘤患者
2. A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer [J] . Walter Urba, Bartosz Chmielowski, Deryk Loo, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：MGA271联合ipilimumab在B7-H3表达黑素瘤，头颈部鳞状细胞癌或非小细胞肺癌患者中进行的I期开放标签剂量递增研究
3. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma [J] . KaufmanJ.L., NiesvizkyR., StadtmauerE.A., British Journal of Haematology . 2013,第4期

机译：在复发或难治性多发性骨髓瘤中使用米拉妥珠单抗（人源化抗CD74单克隆抗体）单药治疗的I期多中心剂量递增试验
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. Interim results of an ongoing Phase I dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 [O] . John Powderly, Gregory Cote, Keith Flaherty, 2015

机译：正在进行的MGA271（Fc优化的人源化抗B7-H3单克隆抗体）I期剂量递增研究的中期结果用于难治性B7-H3表达肿瘤或脉管系统表达B7-H3的肿瘤患者
6. A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer [O] . Walter Urba, Bartosz Chmielowski, Deryk Loo, 2015

机译：MGA271联合ipilimumab在B7-H3表达黑素瘤，头颈部鳞状细胞癌或非小细胞肺癌患者中进行的I期开放标签剂量递增研究
7. Humanized Monoclonal Antibody Specific to the Extracellular Domain of PSMA: Dose Escalation Trial in Patients with Prostate Cancer [R] . Vallabhajosula, S. 2003

机译：psma细胞外区特异性人源化单克隆抗体：前列腺癌患者的剂量递增试验

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

著录项

引文网络

相似文献

相关主题

期刊订阅